Jaguar Health Inc (JAGX)

05:49 AM

Is Jaguar Health Inc. a good long term investmentConsistent triple-digit returns - PrintWeekIndia

05:49 AM

04:03 AM

What drives Jaguar Health Inc. stock priceRapid capital growth - PrintWeekIndia

04:03 AM

Jul 23, 2025

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - Sentinel-Standard

Jul 23, 2025

Jul 23, 2025

What analysts say about Jaguar Health Inc. stockSkyrocketing investment returns - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

Jaguar Health Inc. Stock Analysis and ForecastAccelerated investment success - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Form DEF 14A Jaguar Health, Inc. For: Aug 19 - StreetInsider

Jul 21, 2025

Jul 20, 2025

Published on: 2025-07-20 16:31:40 - Autocar Professional

Jul 20, 2025

Jul 16, 2025

Jaguar Health Announces Amendment to March 2020 Equity Purchase Agreement with Oasis Capital, LLC - FinancialContent

Jul 16, 2025

Jul 11, 2025

Jaguar Health Initiates Enrollment in Canalevia-CA1 Study for Chemotherapy-Induced Diarrhea in Dogs, Eyes EU Expansion. - AInvest

Jul 11, 2025

Jul 10, 2025

Clinical Trial Launches for First FDA-Approved Dog Diarrhea Treatment, Targeting $6B Pet Health Market - Stock Titan

Jul 10, 2025

Jul 09, 2025

Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer - ACCESS Newswire

Jul 09, 2025

Jul 08, 2025

Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS In - El Paso Times

Jul 08, 2025

Jul 08, 2025

Groundbreaking Deal: Peru Grants Access to Sacred Coca Plant for Mental Health Drug Research - Stock Titan

Jul 08, 2025

Jul 07, 2025

Investors Give Jaguar Health, Inc. (NASDAQ:JAGX) Shares A 36% Hiding - 富途牛牛

Jul 07, 2025

Jul 05, 2025

Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Has Been Accepted for Review - ACCESS Newswire

Jul 05, 2025

Jul 04, 2025

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Lohud

Jul 04, 2025

Jul 02, 2025

Jaguar Stock Price: Here’s current price trends, stock performance, key drivers, risks, forecast and more - The Economic Times

Jul 02, 2025

Jun 30, 2025

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient - Worcester Telegram

Jun 30, 2025

Jun 30, 2025

Breakthrough Treatment Reduces Parenteral Nutrition by 27% in Orphan Disease PatientsNew Clinical Data - Stock Titan

Jun 30, 2025

Jun 27, 2025

Jaguar Health (JAGX) Announces $3.37M At-The-Market Stock Offering | JAGX SEC FilingForm 424B5 - Stock Titan

Jun 27, 2025

Jun 26, 2025

Jaguar Health (JAGX) Adopts Cryptocurrency as Treasury Asset | JAGX Stock News - GuruFocus

Jun 26, 2025

Jun 26, 2025

Jaguar Health considers cryptocurrency for treasury reserves - Investing.com

Jun 26, 2025

Jun 25, 2025

Jaguar Health (JAGX) Targets EU Approval for Canalevia in Dogs | - GuruFocus

Jun 25, 2025

Jun 25, 2025

Jaguar Health (JAGX) Targets EU Approval for Canalevia in Dogs | JAGX Stock News - GuruFocus

Jun 25, 2025

Jun 25, 2025

Jaguar Health seeks EU approval for dog diarrhea treatment - Investing.com

Jun 25, 2025

Jun 24, 2025

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 - The Columbus Dispatch

Jun 24, 2025